EMA and FDA harmonise over development of Gaucher drugs

05:51 EDT 5 Jul 2017 | Pharmafile

The EMA and the FDA have announced that they have developed a joint proposal to promote more efficient means of bringing through treatments for Gaucher disease. The proposal may serve to form a template for future drug development within rare diseases, if it were adopted and proved successful.

The two major strategies promoted by the agencies are:

read more

Original Article: EMA and FDA harmonise over development of Gaucher drugs


More From BioPortfolio on "EMA and FDA harmonise over development of Gaucher drugs"

Quick Search


Relevant Topics

Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...